A Phase II, Randomized, Placebo-Controlled, Double-Blind Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease
A Phase II, Randomized, Placebo-Controlled, Double-Blind Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease
The purpose of this study is to evaluate the safety and cholesterol lowering effects of MPSK3169A when given as subcutaneous (SC) injections over a 24-week period to patients with a high risk of cardiovascular events and LDL-c levels well above goal.
Inclusion Criteria:
And at least one of the following:
Exclusion Criteria:
The above list is not intended to contain all factors relevant to a patient's eligibility for the study.
Ponte Verde, Florida 32081, United States
Jičícin, 50601, Czechia
Ostrava - Poruba, 708 52, Czechia